key: cord-0825299-5e1z4lrb
authors: Şahin, Ayça Sultan; Irak, Kader; Kaya, Ebru; Ozkan, Sureyya; Baskan, Fikret
title: A thrombotic complication of COVID-19: cerebral ischaemia in the intensive care unit
date: 2020-09-10
journal: Arch Med Sci Atheroscler Dis
DOI: 10.5114/amsad.2020.98920
sha: 58a778883c7f4837d8375904100e27328a814b4c
doc_id: 825299
cord_uid: 5e1z4lrb

nan

A thrombotic complication of COVID-19: cerebral ischaemia in the intensive care unit Ayça Sultan Şahin 1 , Kader Irak 2 , Ebru Kaya 1 , Sureyya Ozkan 1 , Fikret Baskan 3 COVID-19 may predispose to thromboembolic disease due to severe inflammation, hypoxia, and immobilisation [1] . The severe hypercoagulable state of COVID-19 patients includes systemic micro-and macrovascular thrombosis. Anticoagulant therapy, mainly with low-molecular-weight heparin, appears to be associated with better prognosis in severe COVID-19 patients [2] .

A 45-year-old non-smoking male patient with no chronic disease and normal laboratory blood levels presented with fever, cough, and dyspnoea. Echocardiography did not show atrial fibrillation or atherosclerotic plaque. COVID-19 was diagnosed based on RT-PCR testing. There were no clinical or laboratory signs of a thromboembolic state, and the patient had no history of disseminated intravascular coagulation, venous thromboembolism, or patent foramen ovale shunt. After 4 days, the patient lost consciousness and had a seizure. The patient's illness subsequently progressed to respiratory failure, warranting the initiation of non-invasive mechanical ventilation in the intensive care unit (ICU). Figure 1 depicts the diffusion brain magnetic resonance imaging (MRI) (T2-sequence) with no contrast and shows hyperintense areas in the cortical and subcortical areas at the left temporofrontoparietal level and at the left lentiform nucleus level. Pulmonary angiography (Figure 2 ) findings were compatible with thromboembolism in the right and left lung bases. In the ICU, the patient received antithrombotic therapy: enoxaparin sodium (6000 anti-Xa/0.6 ml, twice a day) and acetylsalicylic acid 100 mg. Levetiracetam 250 mg twice a day was started for seizures. On April 3, 2020, the patient was transferred to the neurological ward. He had right hemiplegia and aphasia.

Available evidence shows that markedly elevated D-dimer levels are associated with high mortality in COVID-19 patients [3] . Multi-organ failure is more likely in patients with sepsis if they develop coagulopathy, and inhibiting thrombin generation may have benefits in reducing mortality [4] . If there are no contraindications for patients requiring hospital admission for COVID-19 infection, prophylactic doses of low-molecular-weight heparin should be administered. The prophylactic enoxaparin dose recommended by the International Society of Thrombosis and Haemostasis on March 25, 2020 is 4000 U [3] . However, we suggest that this prophylactic dose is not sufficient to protect against thromboembo-lism. In many ICUs, higher doses have been used with the same rationale, confirmed by the data from Klok et al. from 184 patients, in whom most events (81%) were pulmonary embolism [5] .

Antiphospholipid antibodies are common in the general population, especially during infection [6] . COVID-19 may induce a hypercoagulable state with elevated fibrinogen and prolonged PT and aPTT. The mechanisms underlying coagulopathy are not clear [7] . Zhang et al. reported that SARS-CoV-2 infection is associated with coagulopathy, thrombocytopaenia, and the presence of anticardiolipin IgA, anti-β2-glycoprotein I, IgA, and IgG antibodies, all of which are responsible for cerebral infarcts [8] . Lodigiani et al. analysed the rate, timing, and characteristics of venous/arterial thromboembolic complications among COVID-19 patients. Their results revealed that thromboembolic complications might represent an integral part of the COVID-19 disease and may already be present at the time of initial hospital admission [9] . We suggest that hypercoagulability caused by COVID-19 may cause ischaemia not only in the lungs but also in vital organs such as the brain. 

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Sepsis Definitions Task Force. Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Coagulopathy of COVID-19 and antiphospholipid antibodies

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Coagulopathy and antiphospholipid antibodies in patients with COVID-19

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

The authors declare no conflict of interest.R e f e r e n c e s